Evidence map›Paper›PMID 29067301›Full record

ArticleAlzheimer's & dementia (New York, N. Y.)2016

NPT088 reduces both amyloid-β and tau pathologies in transgenic mice.

Jonathan M Levenson, Sally Schroeter, Jenna C Carroll, Valerie Cullen, Eva Asp, Ming Proschitsky, Charlotte H-Y Chung, Sharon Gilead, Muhammad Nadeem, Hemraj B Dodiya and 8 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia (New York, N. Y.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03008161 (A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose Escalation Study of NPT088 in Patients With Probable Alzheimer's Disease), which is not on this map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03008161 phase1completednot on this map

A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose Escalation Study of NPT088 in Patients With Probable Alzheimer's Disease

TypeinterventionalSponsorProclara Biosciences, Inc.Ran2016 to 2019Enrolled83ConditionsAlzheimer DiseaseArmsNPT088, Placebo
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 45 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022
    Article
  7. Review
  8. Review
  9. Therapeutics in the Pipeline TargetingPharmacological reviews · 2022
    Review
  10. Review
  11. Feasibility of short imaging protocols for [European journal of nuclear medicine and molecular imaging · 2021
    Article
  12. Review
  13. Review
  14. Review
  15. Current and Future Treatments in Alzheimer Disease: An Update.Journal of central nervous system disease · 2020
    Review
  16. Review
  17. Review
  18. Review
  19. Precision pharmacology for Alzheimer's disease.Pharmacological research · 2018
    Review
  20. Designer protein disaggregases to counter neurodegenerative disease.Current opinion in genetics & development · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 2 countries.

Jonathan M LevensonNeuroPhage Pharmaceuticals, Inc., Cambridge, MA, USA.
Sally SchroeterNeuroPhage Pharmaceuticals, Inc., Cambridge, MA, USA.
Jenna C CarrollNeuroPhage Pharmaceuticals, Inc., Cambridge, MA, USA.
Valerie CullenNeuroPhage Pharmaceuticals, Inc., Cambridge, MA, USA.
Eva AspNeuroPhage Pharmaceuticals, Inc., Cambridge, MA, USA.
Ming ProschitskyNeuroPhage Pharmaceuticals, Inc., Cambridge, MA, USA.
Charlotte H-Y ChungNeuroPhage Pharmaceuticals, Inc., Cambridge, MA, USA.
Sharon GileadNeuroPhage Pharmaceuticals, Inc., Cambridge, MA, USA.
Muhammad NadeemDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Hemraj B DodiyaDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Shadiyat ShoagaDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Elliott J MufsonDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Haim TsuberyNeuroPhage Pharmaceuticals, Inc., Cambridge, MA, USA.
Rajaraman KrishnanNeuroPhage Pharmaceuticals, Inc., Cambridge, MA, USA.
Jason WrightNeuroPhage Pharmaceuticals, Inc., Cambridge, MA, USA.
Beka SolomonDepartment of Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv, Israel.
Richard FisherNeuroPhage Pharmaceuticals, Inc., Cambridge, MA, USA.
Kimberley S GannonNeuroPhage Pharmaceuticals, Inc., Cambridge, MA, USA.
NeuroHealing Pharmaceuticals (United States) · USRush University Medical Center · USTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAlzheimer's disease (AD) is characterized by appearance of both extracellular senile plaques and intracellular neurofibrillary tangles, comprised of aggregates of misfolded amyloid-β (Aβ) and hyper-phosphorylated tau, respectively. In a previous study, we demonstrated that g3p, a capsid protein from bacteriophage M13, binds to and remodels misfolded aggregates of proteins that assume an amyloid conformation. We engineered a fusion protein ("NPT088") consisting of the active fragment of g3p and human-IgG

methodsAged Tg2576 mice or rTg4510 mice received NPT088 weekly via IP injection. Cognitive and/or functional motor endpoints were monitored during dosing. Pathology was quantified biochemically and immunohistochemically.

resultsNPT088-lowered Aβ plaque and improved cognitive performance of aged Tg2576 mice. Moreover, NPT088 reduced phospho-tau pathology, reduced brain atrophy, and improved cognition in rTg4510 mice. DISCUSSION: These observations establish NPT088 as a novel therapeutic approach and potential drug class that targets both Aβ and tau, the hallmark pathologies of AD.

Indexed as

Brain weightCerebrospinal fluidGAIMGeneral amyloid interaction motifLimb claspingNovel object recognitionPhospho-tauSpontaneous alternationThioflavin S

Identifiers

PMID29067301
PMCPMC5651359
OpenAlexW2469188549

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.